Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


6-9 November, 2018
Postillion Convention Center,
Amsterdam, Netherlands

Improve delivery and drive products to market through expert insight, new data and technology for oligonucleotide therapeutics

Mark your calendar for this year's meeting, held 6-9 November, 2018 in Amsterdam.

Sign up for email updates below to receive program updates and early registration offers!

Topics for this year's event:

Delivery of Oligonucleotides and R&D Strategies
  • Targeted Delivery to the Liver and Beyond:
  • New Routes of Delivery for Oligonucleotides:
  • Quantification of Biodistribution of Oligonucleotides
  • R&D and Innovative Chemistries
Manufacturing and Scale Up Strategies
  • Innovative Process Development, Scale Up and Synthesis Strategies for Oligonucleotide Therapeutics to Reduce Cost of Goods
  • New Chemistries for Large Scale, High Throughput Synthesis of More Complex Oligos
  • New Developments in Oligonucleotide Scale Up and Manufacturing Case Studies
  • Quality Control Strategies for Oligo Starting Materials
  • Downstream Processing and Purification Techniques:
  • Formulation and Late Stage Drug Product Development and Manufacturing
mRNA Therapeutics
  • Discovery And Development Of mRNA Therapeutics
  • Preclinical And Clinical Development: Advancing mRNA Products Into The Clinic
  • Strategies To Overcome The Delivery Challenges For mRNA Delivery
  • Formulation Strategies
  • mRNA Analytical And CMC Strategies – Understanding And Measuring Key Quality Attributes For mRNA Therapeutics
  • Optimising Large Scale Manufacturing And Scale Up Of mRNA Therapeutics
  • Regulatory Pathways For mRNA Therapeutics
CRISPR and Genome Editing Applications
  • Advancing CRISPR /Cas9 for Therapeutic Applications
  • Overcoming the Challenges of In Vivo Delivery of Oligonucleotides with CRISPR
Non-Clinical Oligonucleotide Development
  • Update on Safety Issues Emerging for Oligonucleotide Therapeutics
  • Nonclinical Strategies for Translation of Oligonucleotide Therapeutics into the Clinic
  • Nonclinical Development Lessons Learnt to Support Clinical Investigations
Preclinical and Clinical Development of Oligonucleotide Therapeutics

Case study presentations on the latest preclinical and clinical developments for oligonucleotide therapeutics:

  • Antisense
  • siRNA
  • RNAi
  • LNA
  • Aptamers
  • DNA, Immunomodular Nucleic Acids and Combinations with Checkpoint Inhibitors
CMC and Analytical Method Development Strategies
  • Analytical Method Development and Validation for Oligonucleotide Therapeutics
  • Oligonucleotide Impurities and Purity Profiles
  • CMC Challenges and Quality Control Strategies


Highlight your company's expertise to 300+ scientists and key decision makers working across peptide & oligonucleotide development.  For pricing and package options, or to request the latest attendee list, please contact:

Perri Lucatello | +44 (20) 7017 7247

Linda Cole | +44 (20) 7017 6631